Does thermal ablation plus chemotherapy improve survival in small-cell lung cancer ineligible for surgery?
Mao Sun, Yu Zhang, Yangyang Tang, Shubo Han, Wanyi Zhang, Ming Xie · 2026
Read Does thermal ablation plus chemotherapy improve survival in small-cell lung cancer ineligible for surgery? by Mao Sun, Yu Zhang, Yangyang Tang, Shubo Han, Wanyi Zhang, Ming Xie (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13655891.txt.
Description
Mao Sun and co-authors ask if heat ablation plus chemotherapy extends life in small-cell lung cancer in a 2026 study. Surgery is not an option for many of these patients. Heat ablation is known to be safe in another lung cancer type. Evidence in small-cell disease, though, has been scarce.
Records came from a large United States cancer registry for 2000 to 2019. Over fifty-one thousand patients who got chemotherapy were tracked. Matching balanced the ablation-plus-drug group against drugs alone. The combined group lived longer overall and longer free of cancer death. Gains were clearest in patients aged seventy or above. Small tumors and early node stages also benefited most. No clear gain showed in larger or more spread cases. The authors call the combo a promising option for selected patients.
Catalog record
| CREATOR | Mao Sun, Yu Zhang, Yangyang Tang, Shubo Han, Wanyi Zhang, Ming Xie |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 36 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |